Vertex Ventures and Treo Ventures led a $23m Series D round in Neuspera Medical.

Vertex Ventures, a global network of funds, and Treo Ventures, a venture capital firm, led a $23m Series D round in Neuspera Medical, a neuromodulation company, with participation from Action Potential Venture Capital, Windham Venture Partners, and Olympus Innovation Ventures. "As a partner of choice for innovators in urology, we are thrilled to invest in the Neuspera team as they bring the Neuspera System through FDA approval and to the market. Based on critical unmet market need and patient demand, changes in society guidelines, and positive feedback from patients and physicians in clinical trials, we are excited to invest in the Neuspera team as they build their innovative Neuspera System for OAB," Gabriela Kaynor, Olympus Innovation Ventures President.